204 related articles for article (PubMed ID: 31439824)
1. Serial measurements of cardiac troponin I in heart failure secondary to canine mitral valve disease.
Chan IP; Wu SY; Chang CC; Chen WY
Vet Rec; 2019 Sep; 185(11):343. PubMed ID: 31439824
[TBL] [Abstract][Full Text] [Related]
2. Serial analysis of serum cardiac troponin I changes and correlation with clinical findings in 46 dogs with mitral valve disease.
Polizopoulou ZS; Koutinas CK; Dasopoulou A; Patsikas M; York M; Roman I; Gandhi M; Patel S; Koutinas AF; O'Brien PJ
Vet Clin Pathol; 2014 Jun; 43(2):218-25. PubMed ID: 24612252
[TBL] [Abstract][Full Text] [Related]
3. Cardiac troponin-I concentration, myocardial arteriosclerosis, and fibrosis in dogs with congestive heart failure because of myxomatous mitral valve disease.
Falk T; Ljungvall I; Zois NE; Höglund K; Olsen LH; Pedersen HD; Häggström J
J Vet Intern Med; 2013; 27(3):500-6. PubMed ID: 23551840
[TBL] [Abstract][Full Text] [Related]
4. Correlation of serum cardiac troponin I and acute phase protein concentrations with clinical staging in dogs with degenerative mitral valve disease.
Polizopoulou ZS; Koutinas CK; Cerón JJ; Tvarijonaviciute A; Martínez-Subiela S; Dasopoulou A; York MJ; Roman IF; Gandhi M; Patel S; O'Brien PJ
Vet Clin Pathol; 2015 Sep; 44(3):397-404. PubMed ID: 26288324
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-to-lymphocyte ratio is increased in dogs with acute congestive heart failure secondary to myxomatous mitral valve disease compared to both dogs with heart murmurs and healthy controls.
DeProspero DJ; Hess RS; Silverstein DC
J Am Vet Med Assoc; 2023 Nov; 261(11):1-8. PubMed ID: 37406992
[TBL] [Abstract][Full Text] [Related]
6. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
Rasmussen CE; Falk T; Zois NE; Moesgaard SG; Häggström J; Pedersen HD; Ablad B; Nilsen HY; Olsen LH
J Vet Intern Med; 2012; 26(1):76-84. PubMed ID: 22151356
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of pulmonary hypertension in Cavalier King Charles spaniels compared with other breeds with myxomatous mitral valve disease.
Sudunagunta S; Green D; Christley R; Dukes-McEwan J
J Vet Cardiol; 2019 Jun; 23():21-31. PubMed ID: 31174726
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease.
Druzhaeva N; Nemec Svete A; Ihan A; Pohar K; Domanjko Petrič A
J Vet Intern Med; 2021 Sep; 35(5):2112-2122. PubMed ID: 34236111
[TBL] [Abstract][Full Text] [Related]
9. Untargeted metabolomic profiling of dogs with myxomatous mitral valve disease and congestive heart failure shows metabolic differences associated with the presence of cardiac cachexia.
Freeman LM; Rush JE; Karlin ET
Am J Vet Res; 2023 Dec; 84(12):. PubMed ID: 38041949
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of serum ionized magnesium concentration in dogs with myxomatous mitral valve disease.
Kim OK; Kim K; Park S; Yang H; Kim H; Ro WB; Lee CM
J Vet Intern Med; 2024; 38(1):41-50. PubMed ID: 38064361
[TBL] [Abstract][Full Text] [Related]
11. Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study.
Boswood A; Gordon SG; Häggström J; Vanselow M; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
J Vet Intern Med; 2020 May; 34(3):1108-1118. PubMed ID: 32200574
[TBL] [Abstract][Full Text] [Related]
12. Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease.
Reimann MJ; Ljungvall I; Hillström A; Møller JE; Hagman R; Falk T; Höglund K; Häggström J; Olsen LH
Vet J; 2016 Mar; 209():113-8. PubMed ID: 26831162
[TBL] [Abstract][Full Text] [Related]
13. Predictors of reoccurrence of congestive signs within 180 days after successful treatment of the first episode of congestive heart failure in dogs with myxomatous mitral valve disease.
Franchini A; Abbott JA; Tyrrell W; Rosenthal S; Lahmers S; Menciotti G; Crosara S; Häggström J; Borgarelli M
J Vet Cardiol; 2021 Apr; 34():112-119. PubMed ID: 33706221
[TBL] [Abstract][Full Text] [Related]
14. Correlation between serum homocysteine concentration and severity of mitral valve disease in dogs.
Lee CM; Jeong DM; Kang MH; Kim SG; Han JI; Park HM
Am J Vet Res; 2017 Apr; 78(4):440-446. PubMed ID: 28345991
[TBL] [Abstract][Full Text] [Related]
15. Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation.
Morgan KRS; Monteith G; Raheb S; Colpitts M; Fonfara S
Vet J; 2020 Sep; 263():105518. PubMed ID: 32928487
[TBL] [Abstract][Full Text] [Related]
16. Cardiac troponin I is associated with severity of myxomatous mitral valve disease, age, and C-reactive protein in dogs.
Ljungvall I; Höglund K; Tidholm A; Olsen LH; Borgarelli M; Venge P; Häggström J
J Vet Intern Med; 2010; 24(1):153-9. PubMed ID: 20002554
[TBL] [Abstract][Full Text] [Related]
17. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
Nakamura K; Kawamoto S; Osuga T; Morita T; Sasaki N; Morishita K; Ohta H; Takiguchi M
J Vet Intern Med; 2017 Mar; 31(2):316-325. PubMed ID: 28145607
[TBL] [Abstract][Full Text] [Related]
18. DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
Borgarelli M; Ferasin L; Lamb K; Bussadori C; Chiavegato D; D'Agnolo G; Migliorini F; Poggi M; Santilli RA; Guillot E; Garelli-Paar C; Toschi Corneliani R; Farina F; Zani A; Dirven M; Smets P; Guglielmini C; Oliveira P; Di Marcello M; Porciello F; Crosara S; Ciaramella P; Piantedosi D; Smith S; Vannini S; Dall'Aglio E; Savarino P; Quintavalla C; Patteson M; Silva J; Locatelli C; Baron Toaldo M
J Vet Cardiol; 2020 Feb; 27():34-53. PubMed ID: 32032923
[TBL] [Abstract][Full Text] [Related]
19. Symmetric dimethylarginine in dogs with myxomatous mitral valve disease at various stages of disease severity.
Valente C; Guglielmini C; Domenech O; Contiero B; Zini E; Poser H
PLoS One; 2020; 15(9):e0238440. PubMed ID: 32870923
[TBL] [Abstract][Full Text] [Related]
20. Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration.
Reimann MJ; Häggström J; Møller JE; Lykkesfeldt J; Falk T; Olsen LH
J Vet Intern Med; 2017 Mar; 31(2):295-302. PubMed ID: 28132441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
